Literature DB >> 26393428

The role of TRPA1 in muscle pain and mechanical hypersensitivity under inflammatory conditions in rats.

J Asgar1, Y Zhang1, J L Saloman1, S Wang1, M-K Chung1, J Y Ro2.   

Abstract

Transient receptor potential cation channel, subfamily A, member 1 (TRPA1) is expressed in muscle afferents and direct activation of these receptors induces acute mechanical hypersensitivity. However, the functional role of TRPA1 under pathological muscle pain conditions and mechanisms by which TRPA1 mediate muscle pain and hyperalgesia are not clearly understood. Two rodent behavioral models validated to assess craniofacial muscle pain conditions were used to study ATP- and N-Methyl-D-aspartate (NMDA)-induced acute mechanical hypersensitivity and complete Freund's adjuvant (CFA)-induced persistent mechanical hypersensitivity. The rat grimace scale (RGS) was utilized to assess inflammation-induced spontaneous muscle pain. Behavioral pharmacology experiments were performed to assess the effects of AP18, a selective TRPA1 antagonist under these conditions. TRPA1 expression levels in trigeminal ganglia (TG) were examined before and after CFA treatment in the rat masseter muscle. Pre-treatment of the muscle with AP18 dose-dependently blocked the development of acute mechanical hypersensitivity induced by NMDA and α,β-methylene adenosine triphosphate (αβmeATP), a specific agonist for NMDA and P2X3 receptor, respectively. CFA-induced mechanical hypersensitivity and spontaneous muscle pain responses were significantly reversed by post-treatment of the muscle with AP18 when CFA effects were most prominent. CFA-induced myositis was accompanied by significant up-regulation of TRPA1 expression in TG. Our findings showed that TRPA1 in muscle afferents plays an important role in the development of acute mechanical hypersensitivity and in the maintenance of persistent muscle pain and hypersensitivity. Our data suggested that TRPA1 may serve as a downstream target of pro-nociceptive ion channels, such as P2X3 and NMDA receptors in masseter afferents, and that increased TRPA1 expression under inflammatory conditions may contribute to the maintenance of persistent muscle pain and mechanical hyperalgesia. Mechanistic studies elucidating transcriptional or post-translational regulation of TRPA1 expression under pathological pain conditions should provide important basic information to further advance the treatment of craniofacial muscle pain conditions.
Copyright © 2015 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AP18; craniofacial; muscle afferents; myositis; trigeminal ganglia

Mesh:

Substances:

Year:  2015        PMID: 26393428      PMCID: PMC4633371          DOI: 10.1016/j.neuroscience.2015.09.042

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  48 in total

Review 1.  TRPA1: A gatekeeper for inflammation.

Authors:  Diana M Bautista; Maurizio Pellegrino; Makoto Tsunozaki
Journal:  Annu Rev Physiol       Date:  2012-09-27       Impact factor: 19.318

2.  Activation of NMDA receptors leads to phosphorylation of TRPV1 S800 by protein kinase C and A-Kinase anchoring protein 150 in rat trigeminal ganglia.

Authors:  Jongseok Lee; Man-Kyo Chung; Jin Y Ro
Journal:  Biochem Biophys Res Commun       Date:  2012-07-10       Impact factor: 3.575

3.  Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines.

Authors:  Lindsey J Macpherson; Adrienne E Dubin; Michael J Evans; Felix Marr; Peter G Schultz; Benjamin F Cravatt; Ardem Patapoutian
Journal:  Nature       Date:  2007-01-21       Impact factor: 49.962

4.  The role of transient receptor potential A 1 (TRPA1) in the development and maintenance of carrageenan-induced hyperalgesia.

Authors:  Ivan J M Bonet; Luana Fischer; Carlos Amílcar Parada; Claudia H Tambeli
Journal:  Neuropharmacology       Date:  2012-10-23       Impact factor: 5.250

5.  TRPV1 and TRPA1 antagonists prevent the transition of acute to chronic inflammation and pain in chronic pancreatitis.

Authors:  Erica S Schwartz; Jun-Ho La; Nicole N Scheff; Brian M Davis; Kathryn M Albers; G F Gebhart
Journal:  J Neurosci       Date:  2013-03-27       Impact factor: 6.167

6.  P2X₃ and TRPV1 functionally interact and mediate sensitization of trigeminal sensory neurons.

Authors:  J L Saloman; M-K Chung; J Y Ro
Journal:  Neuroscience       Date:  2012-11-29       Impact factor: 3.590

7.  Evaluation of pain in rats through facial expression following experimental tooth movement.

Authors:  Lina Liao; Hu Long; Li Zhang; Helin Chen; Yang Zhou; Niansong Ye; Wenli Lai
Journal:  Eur J Oral Sci       Date:  2014-01-15       Impact factor: 2.612

8.  Contribution of transient receptor potential ankyrin 1 to chronic pain in aged mice with complete Freund's adjuvant-induced arthritis.

Authors:  Sheldon R Garrison; Cheryl L Stucky
Journal:  Arthritis Rheumatol       Date:  2014-09       Impact factor: 10.995

9.  TRPA1 mediates bladder hyperalgesia in a mouse model of cystitis.

Authors:  Jennifer J DeBerry; Erica S Schwartz; Brian M Davis
Journal:  Pain       Date:  2014-04-02       Impact factor: 6.961

10.  Deletion of interleukin-6 signal transducer gp130 in small sensory neurons attenuates mechanonociception and down-regulates TRPA1 expression.

Authors:  Philipp Malsch; Manfred Andratsch; Christian Vogl; Andrea S Link; Christian Alzheimer; Stuart M Brierley; Patrick A Hughes; Michaela Kress
Journal:  J Neurosci       Date:  2014-07-23       Impact factor: 6.167

View more
  29 in total

1.  Spontaneous and Bite-Evoked Muscle Pain Are Mediated by a Common Nociceptive Pathway With Differential Contribution by TRPV1.

Authors:  Sheng Wang; Jongseuk Lim; John Joseph; Sen Wang; Feng Wei; Jin Y Ro; Man-Kyo Chung
Journal:  J Pain       Date:  2017-06-29       Impact factor: 5.820

Review 2.  TRPA1 channels: molecular sentinels of cellular stress and tissue damage.

Authors:  Félix Viana
Journal:  J Physiol       Date:  2016-08-01       Impact factor: 5.182

3.  Preclinical studies investigating the neural mechanisms involved in the co-morbidity of migraine and temporomandibular disorders: the role of CGRP.

Authors:  Simon Akerman; Marcela Romero-Reyes
Journal:  Br J Pharmacol       Date:  2020-10-21       Impact factor: 8.739

4.  Roles of TRPV1 and TRPA1 in Spontaneous Pain from Inflamed Masseter Muscle.

Authors:  Sheng Wang; Benjamin Brigoli; Jongseuk Lim; Alisha Karley; Man-Kyo Chung
Journal:  Neuroscience       Date:  2018-06-08       Impact factor: 3.590

Review 5.  A Review of Pain Assessment Methods in Laboratory Rodents.

Authors:  Patricia V Turner; Daniel Sj Pang; Jennifer Ls Lofgren
Journal:  Comp Med       Date:  2019-12-20       Impact factor: 0.982

6.  Phosphorylation of TRPV1 S801 Contributes to Modality-Specific Hyperalgesia in Mice.

Authors:  John Joseph; Lintao Qu; Sheng Wang; Martin Kim; Daniel Bennett; Jin Ro; Michael J Caterina; Man-Kyo Chung
Journal:  J Neurosci       Date:  2019-11-01       Impact factor: 6.167

7.  Inhibition of inflammatory pain and cough by a novel charged sodium channel blocker.

Authors:  Ivan Tochitsky; Sooyeon Jo; Nick Andrews; Masakazu Kotoda; Benjamin Doyle; Jaehoon Shim; Sebastien Talbot; David Roberson; Jinbo Lee; Louise Haste; Stephen M Jordan; Bruce D Levy; Bruce P Bean; Clifford J Woolf
Journal:  Br J Pharmacol       Date:  2021-06-21       Impact factor: 9.473

Review 8.  Transient Receptor Potential (TRP) Ion Channels in Orofacial Pain.

Authors:  Yuhui Luo; Abbie Suttle; Qiaojuan Zhang; Peng Wang; Yong Chen
Journal:  Mol Neurobiol       Date:  2021-01-29       Impact factor: 5.682

Review 9.  Neural Pathways of Craniofacial Muscle Pain: Implications for Novel Treatments.

Authors:  M K Chung; S Wang; J Yang; I Alshanqiti; F Wei; J Y Ro
Journal:  J Dent Res       Date:  2020-05-06       Impact factor: 6.116

10.  Intrathecal administration of TRPA1 antagonists attenuate cyclophosphamide-induced cystitis in rats with hyper-reflexia micturition.

Authors:  Zhipeng Chen; Shuqi Du; Chuize Kong; Zhe Zhang; Al-Dhabi Mokhtar
Journal:  BMC Urol       Date:  2016-06-17       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.